AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00596154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rituximab, Methotrexate, Vincristine, Procarbazine, PBPCs collection, Busulfan, Thiotepa, and Cyclophosphamide
Description: The initial treatment will consist of cycles of 14 days. Each cycle will start with rituximab, which will be given by vein on day 1.~On day 2 you will be admitted to the hospital and will receive 3 other drugs:~Methotrexate will be given by vein over 2 to 3 hours only on day 2. Vincristine will be given as a single injection over a few minutes only on day 2.~Procarbazine is a pill that you will take at bedtime for 7 nights starting on day 2. Procarbazine is only given every other cycle.
Study NCT02818374 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oral accessibility spatula (SAB)
Study NCT00960037 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral vitamin D3
Description: Vitamin D3 50-100 mcg capsule(depending on baseline serum 25(OH)D concentration) daily for 8 weeks.
Study NCT00960037 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo equivalent
Description: One capsule daily for 8 weeks
Study NCT03453762 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: recruitment maneuver
Description: Recruitment maneuver is provided with positive pressure of 30 cmH2O for 10 seconds.
Study NCT03453762 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasonography-guided recruitment maneuver
Description: Recruitment maneuver is guided by ultrasonography.
Study NCT01581749 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: TrueBeam stereotactic body radiosurgery
Description: 36.25Gy to be delivered to the prostate in 5 fractions. There is only 1 arm in this study.
Study NCT01203436 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supplemental Oxygen Management
Description: Supplemental arm with pulse oximetry targeted at 96% to 99% saturation, for at least 2 weeks, and until both eyes were at study endpoints.
Study NCT01203436 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Oxygen Management
Description: Conventional oxygen arm with pulse oximetry targeted at 89% to 94% saturation.
Study NCT04684355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real-time colonoscopic optical diagnosis for colorectal neoplasm
Description: Colonoscopic optical diagnosis by image enhanced technology has been validated as an excellent tool to predict the histology of colorectal polyps and to differentiate the invasion depth of colorectal cancer.
Study NCT02707510 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Growing Resiliency And CouragE with Cancer™ (GRACE)
Description: GRACE is a 6 week curriculum which includes themes illustrated via PowerPoint slides with semi-structured delivery, video presentations, a variety of mindfulness meditation practices, and selected readings that serve to reflect and capture the theme for the week of the curriculum.
Study NCT02250365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous, suprasensory ESS
Description: 1 hour of ESS daily from Monday to Sunday during hospitalization, but no longer than 4th week post-stroke. The ESS will be applied immediately prior to OT/PT training which will include 15 minutes of repetitive, task-oriented upper limb training during the first 30 minutes after cessation of ESS.
Study NCT02250365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent, suprasensory ESS
Description: 1 hour of ESS daily from Monday to Sunday during hospitalization, but no longer than 4th week post-stroke. The ESS will be applied immediately prior to OT/PT training which will include 15 minutes of repetitive, task-oriented upper limb training during the first 30 minutes after cessation of ESS.
Study NCT01347008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil citrate
Description: Oral sildenafil citratre, 50mg b.i.d., 8 weeks
Study NCT01347008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Sugar pill)
Description: Placebo pills similar to sildenafil citrate pills, b.i.d for 8 weeks
Study NCT00459108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given orally
Study NCT00874965 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrostimulation
Description: 50Hz; 0.4 ms; 30 min; 5 times / week
Study NCT00874965 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham stimulation
Description: 30 min; 5 times / week
Study NCT01286181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Twice daily practice of device-guided slow breathing.
Description: Participants are asked to use the slow-breathing device for 20 minutes twice daily, for 8 weeks. Participants receive weekly telephone calls to monitor device use and are encouraged to use pursed-lips when following the breathing tones of the device while exhaling.
Study NCT01847417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one
Description: Formulation Test 1 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
Study NCT01847417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two
Description: Formulation Test 2 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
Study NCT01847417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA 100 mg tablet
Description: Aspirin® Protect 100 mg tablets (Each tablet contains ASA 100 mg) manufactured by Bayer vital GmbH, 51368 Leverkusen, Germany
Study NCT00832325 — intervention group
Intervention type: BEHAVIORAL
Intervention: interview
Description: The doctor and/or one of her trained research study staff will ask the patient about their experience as an adolescent/young adult cancer survivor, their health and quality of life. It should take (approximately 1-1 ½ hours)to complete. Interviews will be audiotaped and transcribed by a professional transcription service.
Study NCT00832325 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus groups
Description: The patient will participate with 6-8 other adolescent/young adult cancer survivors. The doctor and/or her trained research study staff will ask about their experience as an adolescent/young adult cancer survivor, their health and quality of life. It should take about one-and-a-half hour to complete. Focus groups will be audio taped and transcribed by a professional transcription service.
Study NCT00832325 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: The patient will be asked to participate in three 60-90 minute telephone interviews conducted by the doctor and/or her trained research study staff scheduled at the patient's convenience, the second interview approximately 6-8 months after the first and the last interview approximately 12-16 months after the first. The questionnaire will ask about their experience as an adolescent/young adult cancer survivor, their health and quality of life.
Study NCT03396367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PARTNER
Description: The PATRNER intervention addresses, drug use, PrEP uptake/adherence, and HIV transmission risk by enhancing communication skills by integrating motivational interviewing and video-based communication skills training.
Study NCT03396367 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education Intervention
Description: The Education intervention consists of a 4-session health education intervention that addresses sexual risk and substance use through a lecture and question and answer format.
Study NCT01847417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg gastro-resistant tablet
Description: Protium® 20 mg gastro-resistant tablets (Each gastro-resistant tablet contains 20 mg of pantoprazole (as sodium sesquihydrate)) marketing authorisation holder Nycomed GmbH, Byk-Gulden-Straβe 2, D-78467, Konstanz, Germany
Study NCT04326140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robotic-assisted training
Description: The hand brace is worn on the dorsal side of the impaired hand with 2 surface sensors attached to the extensor and flexor muscles of the arm to detect the surface electromyographic signals (sEMG) for active participation during exercise. The sEMG signals are processed so the patient can visualise the active movement of the muscle where sEMG electrodes are positioned. Different training modes allow the therapist to customise the level of assistance that the Hand of Hope provides. The difficulty level of each mode can be adjusted according to the patient's need.
Study NCT04326140 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: robotic-assisted training
Description: The hand brace is worn on the dorsal side of the impaired hand with 2 surface sensors attached to the extensor and flexor muscles of the arm to detect the surface electromyographic signals (sEMG) for active participation during exercise. The sEMG signals are processed so the patient can visualise the active movement of the muscle where sEMG electrodes are positioned. Different training modes allow the therapist to customise the level of assistance that the Hand of Hope provides. The difficulty level of each mode can be adjusted according to the patient's need.
Study NCT04326140 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham mirror therapy
Description: The mirror was masked. The intervention was the same as the mirror therapy.
Study NCT03307044 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Therapy
Description: Undergo fractional CO2 laser therapy
Study NCT03307044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00274261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C31G
Description: The subject will insert one applicator of C31G prior to each episode of vaginal intercourse during her participation in the study.
Study NCT01641770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional beverage 10003RF
Description: 2 sachets per day
Study NCT01641770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Counseling
Description: Guidelines for dietary counseling include energy and nutrient requirements.
Study NCT01641770 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Counseling
Description: Guidelines for dietary counseling include energy and nutrient requirements.
Study NCT00274261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nonoxynol-9 (N-9)
Description: The subject will insert one applicator of Conceptrol® vaginal gel (nonoxynol-9) prior to each episode of vaginal intercourse during her participation in the study.
Study NCT04071106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Turmeric Extract
Description: Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
Study NCT03579160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% timolol gel with full-thickness skin grafts
Description: Timolol 0.25% gel will be applied to wound bed immediately after surgery before dressing is applied.
Study NCT03579160 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vaseline dressing
Description: Vaseline will be applied to wound bed immediately after surgery before dressing is applied.
Study NCT01613729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 5 mg
Description: Rosuvastatin 5 mg
Study NCT01613729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 10 mg
Study NCT01622153 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Formocresol application after pulpotomy preparation
Description: 1:5 Buckley's Formocresol dilution applied for 5 minutes or until hemostasis achieved
Study NCT04071106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Turmeric Extract in Olive oil
Description: Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
Study NCT04071106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Petrolatum
Description: Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
Study NCT01622153 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GENTLEray 980 Soft Tissue diode laser
Description: Application to pulp chamber until hemostasis achieved
Study NCT01596608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy (MagPro MST)
Description: 100% machine output at between 25 and 100 Hz, with coil directed over frontal or vertex brain regions, until adequate seizure achieved. Six treatment sessions, at a frequency of two or three times per week will be administered. If subjects fail to achieve the pre-defined criteria of remission at that point, the dose will be increased to the maximal stimulator output and 3 additional treatment sessions will be provided. This will be repeated a total of 5 times (i.e., maximum treatment number is 24). 24 treatments is typically longer that a conventional ECT treatment course. However, evidence does suggest that longer treatment courses may be needed with MST, particularly in more treatment resistant psychiatric conditions such as OCD and schizophrenia.
Study NCT00726804 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab)
Description: Discontinuation of infusion infliximab (Remicade) 3-5mg/kg every 6-8 week, injection of etanercept (Enbrel) 25 mg x 2/week or injection of adalimumab (Humira) 40 mg eow.
Study NCT01457521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen
Study NCT01190878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISV-303
Description: 0.075% of bromfenac in DuraSite dosed QD
Study NCT01190878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISV-303
Description: 0.075% of bromfenac in DuraSite dosed BID
Study NCT01190878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DuraSite Vehicle
Description: Vehicle dosed BID
Study NCT01190878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xibrom™
Description: 0.09% bromfenac dosed BID
Study NCT02075450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPRcard
Description: CPR Card in place during chest compressions to provide immediate visual feedback.
Study NCT02075450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Just in Time Video
Description: CPR Just in Time training video administered before the simulation case
Study NCT02157298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Description: Dapagliflozin, a blood glucose lowering drug. Oral dose
Study NCT02157298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet. Oral dose
Study NCT02315378 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TAU
Description: Treatment as Usual for patients presenting after accidents and assaults as it pertains to mental health, is a brief intervention that varies in length depending on the patient's needs. If the patient is highly distressed, the social worked will provide brief crisis management support. The social worker also performs case management functions such as attempting to get in touch with family, contacting shelter or hotel if the patient is homeless, contacting other social service agencies if needed, and providing the patient referrals for mental health services in the community. A psychiatrist will also be called to assess the patient only if he or she appears to be a threat to self (suicidal) or others, and exclusion criteria for this study.
Study NCT02315378 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ARTAT
Description: A one-session intervention targeting at-risk individuals (those continuing to experience peritraumatic panic following a trauma) and designed to reduce peritraumatic anxiety and enhance self-efficacy.
Study NCT04071106 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NB-UVB
Description: Patients will receive 2 sessions of NB-UVB phototherapy and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
Study NCT04071106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcipotriol/ Betamethasone
Description: Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
Study NCT00091988 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle & Behavioral Change Program
Description: Participants in the weight loss arm will receive an intensive group-based behavioral weight loss program. In the first six months of the intervention, all participants in the weight loss arm will be given skill-based diet and exercise prescriptions for weight loss and will be taught specific cognitive and behavioral skills to assist in the modification of their eating and exercise habits. Participants will meet weekly for 6 months in group sessions led by a nutritionist, exercise physiologist, or behaviorist and will follow a structured protocol. This intervention strategy is modeled on interventions that have been successful in other overweight populations and is similar to the programs implemented in our ongoing studies, such as Look AHEAD. With this intervention, women are expected to lose on average of 7-9% of their initial body weight.
Study NCT00091988 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured Education Program
Description: Women randomized to the Structured Education Program will be invited to participate in hour long group educational sessions at months 1, 2, 3, and 4. At months 6, 9 and 15, the groups will meet again for group support sessions. The content of these education and support sessions will include information about weight loss, physical activity, healthy eating habits and general health promotion. The educational sessions will be delivered primarily in a group format, with individual make up sessions provided for participants who miss group sessions.
Study NCT01904097 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin 150 mg per oral BID (i.e. twice per day).
Study NCT01904097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 150 mg per oral BID (i.e. twice per day).
Study NCT04874727 — intervention group
Intervention type: PROCEDURE
Intervention: Mandible slacked and captured with Correct Plus™ Impression Material Superfast
Description: In order to simulate the supine position, patients are placed in a supine position (180 degrees) in a dental exam chair, and asked to relax their lower jaw, allowing it to drop back, simulating their jaw falling back while sleeping. That bite is then captured with a Correct Plus™ Impression Material Superfast. Once the bite material hardens, it locks the bite in place. The patient then stands upright, and CBCT is taken standing while the jaw placement is still pseudo sleep-supine, supported by the bite material.
Study NCT00814398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double Embryo Transfer (DET)
Description: Two embryos are transferred during an IVF treatment
Study NCT01904097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: The tDCS consists of application of low intensity direct current (2 mA), with the anode placed in the dominant motor cortex (M1) and the cathode in the ipsilateral supraorbital region during 30 minutes each session, using sponge electrodes soaked with normal saline solution.
Study NCT01904097 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 30 minutes that the session lasts.
Study NCT03515369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Babaodan oral capsule
Description: On the basis of conventional liver protecting treatment, take Babaodan oral capsule within 4 weeks after curative resection. Take two capsules three times daily, two months as a course of treatment and the maximum of eighteen courses, until the recurrence of tumor or death of patients (non tumor related death), or the termination of research.
Study NCT03515369 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: On the basis of conventional liver protecting treatment, take Placebo oral capsule began within 4 weeks after curative resection. Take two capsules three times daily, two months as a course of treatment and the maximum of eighteen courses, until the recurrence of tumor or death of patients (non tumor related death), or the termination of research.
Study NCT01856569 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: in real life of drug,dosage,frequency and duration
Study NCT00346320 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: 3-dimensional conformal radiotherapy, 60 Gy in once daily 4 Gy fractions (Monday to Friday) over 3 weeks
Study NCT03506945 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mPEP
Description: Behavioral Activation Therapy